<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATOMOXETINE</span><br/>(a-to-mox'e-teen)<br/><span class="topboxtradename">Strattera<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">norepinephrine reuptake inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 18 mg, 25 mg, 40 mg, 60 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Exact mechanism of action is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine
         transporter, resulting in norepinephrine reuptake inhibition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Improved attentiveness, ability to follow through on tasks with less distraction and forgetfulness, and diminished hyperactivity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of attention deficit/hyperactivity disorder (ADHD) in adults and children.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitive to atomoxetine or any of its constituents; concomitant use or use within 2 wk of MAOIs; narrow angle glaucoma;
         pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe liver injury may progress to liver failure or death in a small percentage of patients. Hypertension, tachycardia, cardiovascular
         or cerebrovascular disease; any condition that predisposes to hypotension; urinary retention or urinary hesitancy; concomitant
         use of CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine), albuterol or other beta-<small>2</small> agonists, vasopressor drugs, safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">ADHD</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 40 mg in morning. May increase after 3 d to target dose of 80 mg/d given either once in the morning or divided
               morning and late afternoon/early evening. May increase to max of 100 mg/d if needed.<br/><span class="rdage">Child/</span><span class="rdage">Adolescent:</span> <span class="rdroute">PO</span>
<i> start with 0.5 mg/kg/d. May increase after 3 d to target dose of 1.2 mg/kg/d. Administer once daily in morning or divide
               dose and give morning and late afternoon/early evening. Max dose is 1.4 mg/kg or 100 mg, whichever is less. <i>&gt;70 kg</i>, the max total daily dose is 100 mg.<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/><span class="rdage">Child-Pugh Class B:</span> <span class="rdroute"></span> Initial and target doses should be reduced to 50% of the normal dose.<br/><span class="rdage">Child-Pugh Class C:</span> <span class="rdroute"></span> Initial dose and target doses should be reduced to 25% of normal.<br/><br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that total daily dose in children and adolescents is based on weight. Determine that ordered dose is appropriate for
            weight prior to administration of drug.
         </li>
<li>Note manufacturer recommends dosage adjustments with concomitant administration of strong CYP2D6 inhibitors (e.g., paroxetine,
            fluoxetine, quinidine). Consult physician.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flu-like syndrome, flushing, fatigue, fever, rigors. <span class="typehead">CNS:</span> Dizziness, <span class="speceff-common">headache,</span> somnolence, crying, tearfulness, irritability, mood swings, <span class="speceff-common">insomnia,</span> depression, tremor, early morning awakenings, paresthesias, abnormal dreams, decreased libido, sleep disorder, <span class="speceff-life">suicidal ideation</span>. <span class="typehead">CV:</span> Increased blood pressure, sinus tachycardia, palpitations. <span class="typehead">GI:</span>
<span class="speceff-common">Upper abdominal pain,</span> constipation, dyspepsia, <span class="speceff-common">vomiting, decreased appetite,</span> anorexia, dry mouth, diarrhea, flatulence, <span class="speceff-life">severe liver injury (rare)</span>. <span class="typehead"> Endocrine:</span>  Hot flushes. <span class="typehead">Metabolic:</span>  Weight loss. <span class="typehead">Hepatic:</span> Hepatotoxicity. <span class="typehead">Musculoskeletal:</span> Arthralgia, myalgia. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cough,</span> rhinorrhea, nasal congestion, sinusitis. <span class="typehead">Skin:</span> Dermatitis, pruritus, increased sweating. <span class="typehead">Special Senses:</span> Mydriasis. <span class="typehead">Urogenital:</span> Urinary hesitation/retention, dysmenorrhea, ejaculation dysfunction, impotence, delayed onset of menses, irregular menstruation,
      prostatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Albuterol</b> may potentiate cardiovascular effects of atomoxetine; <b>fluoxetine,</b>
<b>paroxetine,</b>
<b>quinidine</b> may increase atomoxetine levels and toxicity; <span class="classification">maois</span> may precipitate a hypertensive crisis; may attenuate effects of <span class="classification">antihypertensive agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI trace. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP2D6. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 5.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Evaluate for continuing therapeutic effectiveness especially with long-term use.</li>
<li>Monitor cardiovascular status especially with preexisting hypertension.</li>
<li>Monitor HR and BP at baseline, following a dose increase, and periodically while on therapy.</li>
<li>Lab tests: Periodic LFTs.</li>
<li>Report increased aggression and irritability as these may indicate a need to discontinue the drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: chest pains or palpitations, urinary retention or difficulty initiating voiding
            urine, appetite loss and weight loss, or insomnia.
         </li>
<li>Make position changes slowly if you experience dizziness with arising from a lying or sitting position.</li>
<li>Do not drive or engage in potentially hazardous activities until reaction to the drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>